Key result
Antihypertensive agents modulating the renin-angiotensin-aldosterone system can delay microalbuminuria progression and decrease cardiovascular morbidity and mortality in patients with diabetes.
RAAS-blocking agents can delay microalbuminuria progression and reduce cardiovascular morbidity and mortality in diabetic patients, though the impact of targeting underlying inflammation remains to be determined.
Answers are grounded in this paper and cite their sources.
Confirms RAAS blockade benefits in diabetes; leaves open contribution of anti-inflammatory targeting.
The incidence of type 2 diabetes is increasing in the United States, which is expected to result in an increased prevalence of microalbuminuria and higher cardiovascular risk. Microalbuminuria is an indication that a low-level inflammatory process is ongoing. In patients with hypertension, with or without diabetes, increasing urinary albumin excretion (UAE) is associated with elevated levels of inflammatory markers, endothelial dysfunction, and platelet activation. Microalbuminuria is associated with an increased incidence of cardiovascular disease (CVD) morbidity and mortality in patients with hypertension and in those with diabetes with or without hypertension. Antihypertensive agents that modulate the renin-angiotensin-aldosterone system (RAAS) can delay the onset and reduce progression of microalbuminuria and decrease CVD morbidity and mortality in patients with diabetes. Clinical trials provide a spectrum of results regarding the protective effects of RAAS-blocking agents. Consideration of baseline blood pressure (BP), UAE and CVD risk, and the extent of BP lowering with treatment is necessary when interpreting clinical trial results in patients with microalbuminuria. It remains to be determined whether targeting the underlying inflammatory process can retard or prevent microalbuminuria progression or whether treatment of microalbuminuria can prevent end-stage renal disease or death.
No takes yet. Share an insight, caveat, or question.
Kalaitzidis et al. (2009) conducted a review in Microalbuminuria in patients with diabetes. Renin-angiotensin-aldosterone system (RAAS) modulating agents was evaluated. Antihypertensive agents modulating the renin-angiotensin-aldosterone system can delay microalbuminuria progression and decrease cardiovascular morbidity and mortality in patients with diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: